Valeant Said to Name New CEO With Pearson Still Hospitalized

  • Schiller, Rosiello may be candidates, Wall Street Journal says
  • Pearson remains on medical leave for severe pneumonia

Why Schiller as Interim CEO Is Good for Valeant

Valeant Pharmaceuticals International Inc. will name a new chief executive officer to lead the company while Michael Pearson remains hospitalized after contracting severe pneumonia, a person familiar with the matter said Tuesday.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.